• Ozlem Mermut, Berrin Inanc, GursuRıza UmarRUhttp://orcid.org/0000-0002-6331-3632Acıbadem Bakırköy Hospital, Department of Medical Oncology - Bakırköy, Istanbul. Turkey., Esra Arslan, Didem Can Trabulus, Semiha Battal Havare, and Melis Baykara Ulusan.
• University of Health Sciences Istanbul Training and Research Hospital, Department of Radiation Oncology - Fatih, Istanbul. Turkey.
• Rev Assoc Med Bras (1992). 2021 Jun 1; 67 (6): 845-850.

ObjectiveThe aim of this study was to examine the characteristics of patients admitted to our hospital with a diagnosis of breast cancer who reached pathological complete response after being operated following eight cycles of neoadjuvant chemotherapy.MethodsBetween 2015-2020, patients with pathological complete response who were operated on after neoadjuvant chemotherapy and sent to our clinic for radiotherapy were evaluated.ResultsThe median age of the patients was 51 years. The most common histological type was invasive ductal cancer. The number of pathological complete response patients was 74 (28%), and the number of non-pathological complete response patients was 188 (72%). Patients with pathological complete response had a smaller tumor diameter than the non-pathological complete response group (p=0.001). For pathological complete response, T1 stage, N1 stage, NG 3, Ki-67 >20%, negative estrogen receptor, negative progesterone receptor, positive Cerb-B2, and adding trastuzumab to chemotherapy were statistically significant (p<0.05). Before neoadjuvant chemotherapy, stage T1-T2 (p=0.036), LN0-1 (p=0.026), Cerb-B2 positivity (p=0.025), and an initial nuclear grade of three (p=0.001) were found to be the factors affecting pathological complete response.ConclusionsWith neoadjuvant chemotherapy, the size of locally advanced tumors decreases, allowing breast conserving surgery. The neoadjuvant chemotherapy response can be used as an early indicator of the prognosis of patients with breast cancer. Today, neoadjuvant chemotherapy is also used for patients with early-stage, operable breast cancer because it has been shown in many studies that reaching pathological complete response is associated with positive long-term results. If we can identify patients who have reached pathological complete response before neoadjuvant chemotherapy, we think we can also determine a patient-specific treatment plan at the beginning of treatment.

18 keywords...

hide…